Pre-Open Stock Movers 08/19: (MNTA) (HUD) (IMVT) Higher; (BMRN) (GLPG) (VIPS) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Harry and Meghan surprised by King Charles' letter on their status
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Qualcomm to issue warrant to Amazon for up to 25M shares
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Sangamo (SGMO) Partner Pfizer (PFE) is Encouraged by Emerging Data from SB-525 - Truist Securities
August 20, 2020 10:57 AM EDTTruist Securities analyst Nicole Germino reiterated a Buy rating and $22.00 price target on Sangamo BioSciences (NASDAQ: SGMO) after talking with management following BMRN's unexpected CRL. Management noted partner Pfizer (NYSE: PFE) is encouraged by emerging data from SB-525
The analyst... More
Baird Reiterates Outperform Rating on The TJX Companies (TJX) Following 2Q
August 20, 2020 7:08 AM EDTBaird analyst Mark R. Altschwager reiterated an Outperform rating and $65.00 price target on The TJX Companies (NYSE: TJX) following the company's 2Q earnings report. Sales in the quarter fell 32% with stores closed ~1/3 of the quarter and open-store-comp sales -3%. Management cited some logistical challenges disrupting... More
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $120 at Baird; Sees at Least a 2-Year Valrox Delay Following CRL
August 19, 2020 11:30 AM EDTBaird analyst Michael Ulz lowered the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $120.00 (from $140.00) while maintaining an Outperform rating after the company announced a CRL on Valrox.
The analyst commented, "Overall, we view the update as disappointing and assume at least a two-year delay in time-line."
... More